Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CMV Immunity Monitoring in Lung Transplant Recipients — Stella

Home/Lung Transplant; Complications/CMV Immunity Monitoring in Lung Transplant Recipients

View on ClinicalTrials.gov

Recruiting

Back to Lung Transplant; Complications trials

CMV Immunity Monitoring in Lung Transplant Recipients

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

NYU Langone Health, New York, New York

Key details

Phase

Safety & dosing

Sponsor

NYU Langone Health

Collaborators

Viracor Eurofins

Enrollment target

~50 participants

Started

September 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 99 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.